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Abstract 
Introduction Previous literature has suggested that iatrogenic atrial septal defects (IASD) may 
follow left atrial (LA) access by transseptal (TS) puncture, especially in case of single TS for 
more than one catheter. Aim of the present study is to describe prevalence of patent foramen 
ovale (PFO) and IASDs in a cohort of atrial fibrillation (AF) patients undergoing redo catheter 
ablation (CA) procedures in a high volume center accessing LA by standardized, single TS 
puncture.   
Methods and Results Patients (n=197) who underwent at least one redo AFCA, between 2004 
and 2012, were retrospectively enrolled. Transesophageal echocardiography was performed 
before each procedure during which LA was accessed via a PFO, if present, or by single TS for 
both the mapping and ablation catheters.  
At baseline PFO was detected in 43 (21.8%) patients. Clinical and echocardiographic parameters 
recorded did not differ within patients presenting with or without PFO. LA was accessed via PFO 
in 39 (90.7% of those with PFO) patients during the first procedure. New onset IASD occurred in 
11 (5.6%) patients following the first procedure and in one (2.2%) patient following the second 
procedure. Clinical and echocardiographic parameters did not differ within patients reporting or 
not IASD. No TS-related complications occurred. 
Conclusion In the present cohort LA access by PFO or single TS for both the mapping and 
ablation catheters lead to a small risk of asymptomatic IASD, not increased by redo procedures, 
confirming that it represents a safe approach. No clinical and/or echocardiographic parameters 
seemed to predict IASD occurrence. 
Key-words: atrial fibrillation, ablation, iatrogenic atrial septal defects, patent foramen ovale, 
transseptal puncture 
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Condensed Abstract  
Literature reports controversial data on iatrogenic atrial septal defects (IASD) following atrial 
fibrillation catheter ablation. In our cohort left atrium access by patent foramen ovale or single 
transseptal puncture, for both the mapping and ablation catheters, lead to a small risk of 
asymptomatic IASD, not increased by redo procedures.  
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What’s new? 
LA access via a patent foramen ovale (PFO) or a single transseptal (TS) puncture for both the 
mapping and ablation catheters does not lead to a relevant risk of iatrogenic atrial septal defects 
(IASD).  
Within patients not presenting baseline PFO a minority (6%) reported asymptomatic IASD 
unpredicted by any clinical or echocardiographic characteristics potentially involved.  
In patients undergoing redo atrial fibrillation catheter ablation (AFCA) procedures the present 
study is, to the best of our knowledge, unique. In fact the proposed left atrium (LA) approach 
seems extremely safe also in patients undergoing a second procedure. Based on the present data a 
redo procedure does not increase the risk of IASD. 
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Introduction 
Catheter ablation (CA) has progressively increased its role in the treatment of atrial fibrillation 
(AF), being proposed to date to more than two-hundred thousand patients worldwide1. In the 
latest decades history, in fact, AFCA has significantly evolved becoming pulmonary vein (PV) 
isolation and left atrium (LA) linear lines established procedural targets achieving satisfactory 
long-term outcomes 2,3. To perform the procedure LA access is achieved by a patent foramen 
ovale (PFO), when present, or more commonly by a transseptal (TS) puncture. In the latter case, 
LA access can be obtained both with single TS puncture followed by exchange over the guide 
wire of a second catheter2, or by double TS puncture4, 5, 6.  To date, whether a TS LA 
catheterization involves a risk of persistent iatrogenic atrial septal defect (IASD) is controversial. 
Previous small sample size studies, using transesophageal echocardiography (TEE), reported an  
incidence from null7 to 19% of IASD at mid-term follow up after AFCA5, 6, 8. The only large 
sample size study, based on transthoracic echocardiography (TTE), surprisingly reported the 
absence of IASDs about 1 year following the procedure9. In addition if redo procedures requiring 
new TS punctures increase the incidence of IASD is unknown. 
Aim of the present retrospective study is therefore to report the prevalence of PFO at baseline and 
describe the incidence of IASD by TEE in a large cohort of patients undergoing at least one 
AFCA redo procedure in a high volume center using a standardized LA approach by single TS 
puncture. 
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Methods 
Eight hundred eighty-nine patients referred for AFCA between 2003 and 2012 have been 
screened. Baseline PFO was present in 206 (23.2%) patients and AF recurrences, over the years, 
occurred in 433 (48.7%). Within this population the 197 patients (22.2%) who underwent at least 
one redo procedure were enrolled in the study. Before the indication to AFCA, failure of at least 
two different antiarrhythmic drugs in controlling symptoms of AF or maintaining sinus rhythm 
had to be documented. Redo AFCA was proposed in case of recurrences following the first 
procedure not controlled by one new AAD or in case of patients’ refusal of a new AADs. The 
definition and classification of AF used in this study were based on contemporary published 
guidelines10. All subjects underwent extensive clinical assessment, including: medical history 
(targeted to presence of heart disease and comorbidities), thromboembolic risk assessment 
(CHA2DS2-Vasc score) and physical examination. TTE and TEE were performed before the 
procedure in each patient. The study was conducted in accordance to the latest Declaration of 
Helsinki and all patients signed an informed consent form before undergoing the AFCA 
procedure.  
 
Transthoracic echocardiography. LA (superior-inferior, lateral-medial, anterior-posterior) and 
right atrium diameters (superior-inferior, lateral-medial) were recorded at the end of ventricular 
systole on the M-mode image obtained from the parasternal long axis view or from the apical 2- 
and 4- chambers two-dimensional views as appropriate. Left ventricle ejection fraction (by the 
biplane Simpson’s method of discs), ventricular wall thickness, lumen diameters and 
global/segmental kinesis were assessed according to the latest European Association of 
Echocardiography Guidelines 11.  
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Transesophageal echocardiography. LA and LA appendage were appraised to exclude the 
presence of endoluminal thrombi or spontaneous echocontrast/smoke. LA appendage ostium area 
and peak flow velocity were recorded. The interatrial septum and the fossa ovale were also 
identified in search of any leakage, supported by the color-doppler technique to describe inter-
atrial shunts. Peripheral venous infusion of an echo-contrast solution (aerated saline solution), 
both at rest or during Valsalva maneuver was also performed in all patients in search of any inter-
atrial communication (positive in case of microbubbles appearance in the right atrium within 
three cardiac cycles after the peripheral venous infusion12, 13, 14). The following definitions guided 
PFO and IASD diagnosis. PFO: microbubbles appearance in the right atrium through a passage 
located in the anterior portion of the inter-atrial septum (in proximity to the fossa ovalis). IASD: 
microbubbles appearance in the right atrium through an inter-atrial communication located in the 
posterior portion of the inter-atrial septum (in correspondence of the standard site of TS 
puncture). In addition, in case PFO or IASD were detected, evaluation of shunt presence and 
hemodynamic influence (Qp/Qs) was performed.  
 
Ablation procedure. Procedural details have been reported elsewhere15. Briefly, concerning LA 
access, in the absence of a PFO, a guide wire was introduced into the LA by a single TS puncture 
(BRK Transseptal Needle, St Jude Medical, MN, USA) with the use of an 8.5F long sheath (Fast-
Cath or SL0, St. Jude Medical, MN, USA; the Fast-Cath sheath has been preferentially used in 
patients presenting with PFO). An irrigated-tip 8F ablation catheter (Navistar or Thermocool, 
Biosense Webster, CA, USA; or Coolpath, St. Jude, MN, USA) was then advanced into the LA, 
exchanged over the guide wire, through the same hole (Figure 1). The sheath was continuously 
perfused with heparinized solution (3000 U of heparin in 500 mL of NaCl 0.9%) at 150 mL/h and 
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a multipolar 8F catheter (Lasso, Biosense Webster, CA, USA; or Inquiry Optima, St Jude 
Medical, MN, USA; or Orbiter, Bard, MA, USA) was inserted through the long sheath to map the 
PVs ostia. A 3-dimensional reconstruction of the LA and PVs ostia, with the use of an 
electroanatomic mapping system (Carto, Biosense Webster, CA, USA; or Nav-X, St. Jude, MN, 
USA) was performed in all patients. For paroxysmal AF, the end point of the ablation procedure 
was to obtain a complete electric PVs isolation. If necessary to interrupt the arrhythmia or in case 
of a repeat procedure, PVs isolation plus the addition of linear lesions were performed. For 
persistent AF, PVs isolation was accompanied by the creation of extra linear lesions 
interconnecting the upper pulmonary veins ostia (roof line), and the left inferior pulmonary vein 
down to the mitral annulus (left isthmus); when necessary, a line interconnecting the right 
inferior pulmonary vein to the mitral annulus (right isthmus) and ablation of fragmented atrial 
electrograms were performed to complete elimination of the potentials. Radiofrequency was 
applied with power output up to 30 W close to the PV ostia and up to 40 W while creating the 
roof line and the left mitral isthmus line, with an irrigation rate of 15 to 35 mL/min (0.9% saline 
infused with the Cool Flow Pump, Biosense Webster, CA, USA) to maintain a tip temperature 
below 45°.  
 
Follow up. All patients were regularly followed by ambulatory visits or telephonic monitoring 
and performed 24-hour Holter ECG at 1, 3, 6 months and then yearly to identify occurrence of 
relapses or any new symptom, especially related to thromboembolic events (i.e. transient 
ischemic attack, cerebro-vascular accident). Three (1.5%) patients received an implantable 
continuous recorder. 
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Statistical analysis. 
Continuous variables, presented as means ± standard deviation (SD), were compared by 
Student’s t-test after normal distribution was confirmed. Categorical variables, presented as 
counts and percentages, were compared in cross-tabulation tables by means of the Pearson chi-
square test. The time between AFCA and echocardiographic follow-up were presented as median 
and interquartile range (IQR). All tests of significance were two-tailed, and a p value of less than 
0.05 was considered to indicate statistical significance. All analyses were performed by SPSS 
18.0. 
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Results 
During the ten year period retrospectively investigated at least one redo AFCA procedure was 
performed in 197 patients (76.1% males mean age 57.1±10 years) due to symptomatic drug 
resistant AF relapses. In addition, as shown in details in the flowchart reported in Figure 2, in 45 
(22.8%) patients two redo AFCA procedures were performed.  
At baseline 43 (21.8%) patients (74.4% males mean age 55.0±9 years) presented a PFO. All PFO 
were asymptomatic and none presented, at echocardiographic study, significant hemodynamic 
shunt. As reported in Table 1, clinical or echocardiographic characteristic did not differ within 
patients presenting or not with a baseline PFO. When described, LA was accessible via the PFO 
in the majority of cases (39, 90.7%).  
Following the AFCA procedure, after a median period of 12 (7–25) months, 11 (5.6% of all, 
7.1% of those not presenting baseline PFO) patients developed an asymptomatic IASD (Figure 
3). Out of the 45 (22.8%) patients undergoing a second AFCA redo procedure 13 (28.9%) 
presented a PFO since baseline and 2 (4.4%) had developed an IASD following the first 
procedure. LA access was achieved via PFO in 8 (61.5%) patients presenting PFO and via IASD 
in both the two cases that developed one following the first procedure. Following the second 
AFCA procedure, after a median period of 13 (7–23) months, 1 (2.2% of all, 3.3% of those not 
presenting PFO/IASD) patient developed an asymptomatic IASD. None of IASD detected in our 
study presented, at echocardiographic study, a significant hemodynamic shunt. No clinical, 
echocardiographic and ablation characteristics related to IASD development following the first or 
second AF ablation procedure (Table 2).  
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No TS related complication occurred during the total 439 AFCA procedures retrospectively 
analyzed. 
 
Discussion 
The present retrospective study, performed in a large cohort of patients undergoing at least one 
AFCA redo procedure, supports that LA access via a PFO or a single TS puncture for both the 
mapping and ablation catheters does not lead to a relevant risk of IASD. In fact, within the 
patients presenting a baseline PFO, LA was accessed via this spontaneous anatomical path in the 
majority of cases (91%) without creating long-term complications. Within patients not presenting 
baseline PFO, a minority (6%) reported, instead, asymptomatic IASD unpredicted by any clinical 
or echocardiographic characteristics potentially involved.  
The first study7 on this topic was performed on 51 patients undergoing left sided 
electrophysiological studies by a single TS puncture. In this experience, none of the patients 
reported a post procedural IASD, investigated by TEE, after a mean period of 12 weeks. Years 
later, however, Hammerstingl et al. 5 reported in patients undergoing pulmonary vein isolation 
due to AF a 19% incidence, investigated by TEE, of IASD after a mean period of 9 months. 
Interestingly this study also compared the single and double TS puncture techniques suggesting a 
correlation between single TS puncture and IASD. Within the 42 patients enrolled, 8 new onset 
iASD were reported, all within patients undergoing single TS procedure (n=27). In the latter 
dataset, in addition, increased baseline pulmonary artery pressure estimated by echocardiography 
was significantly related to IASD incidence. Another study by Obel et al.8 instead, although on a 
similar follow-up period (33 weeks) described a lower IASD incidence (6.5%) following a similar 
pulmonary vein isolation procedure achieved by double TS puncture. New insights on the 
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incidence and clinical implications of IASD emerged following the studies by the group of Rillig. 
These authors, in 20086, performed repeated TEE among 31 patients undergoing pulmonary vein 
isolation by double TS puncture; the scans were completed immediately after the procedure and 
at 3, 6 and 12 months thereafter. Immediately after the procedure IASD were detectable in 27 
(87%) patients. Spontaneous closure of the IASD was, however, reported in 26 out of 27 (96.3%) 
already at the 3-month TEE. The only patients in which the defect did not quickly spontaneously 
close maintained this echocardiographic finding, completely asymptomatic, also at the 6 and 12-
months controls. A similar trend towards spontaneous closure was also reported in case of use of 
different technologies for AFCA. Among 40 patients undergoing pulmonary vein isolation by 
means of a remote robotic navigation system involving sheaths with a distinct larger outer 
diameter, the day after the procedure, an IASD was detected in 38 (95%) patients. Spontaneous 
closure of the IASD was, however, achieved at 6-month follow-up in 30 (79%) patients. 
Persistence of IASD over the follow-up did not relate to cerebral or cardiac embolic events16. In 
addition, spontaneous closure of post procedural IASD has also been reported following TS 
puncture due to other indications17. In fact, also in the present dataset, time to redo procedure was 
shorter (7, 2-20 months) for patients who reported IASD compared to those (12.5, 7-26.2) in the 
other group, but this trend did not reach statistical significance (p value 0.131). 
To date, if IASD have this benign evolution also performing a single TS for both mapping and 
ablation catheters remains instead controversial. One large sample size study9 retrospectively 
addressed this topic reporting the absence of IASDs about 1 year following a simplified approach 
for positioning multiple catheters in the LA by single TS puncture but the data were based on 
TTE.  
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With these presumptions the present finding of a low (5.6%) IASD incidence, assessed by TEE, 
following LA access with both the mapping and ablation catheters by single TS puncture is, 
indeed, relevant. Surely this result is influenced by the long period between the procedure and the 
TEE scan. The first redo procedure was, in fact, performed after a median period of 12 months 
(7–25). However, on the other side, evaluating the prevalence of IASD in a population of patients 
undergoing redo AFCA procedures due to arrhythmia relapses could have potentially 
overestimated its presence due to the selective inclusion of patients suffering higher LA 
pressures. 
Concerning, instead, IASD prevalence in patients undergoing redo AFCA procedures the present 
study is, to the best of our knowledge, unique. Also in patients undergoing a second procedure in 
fact the proposed LA approach seems extremely safe. Based on the present data a redo procedure 
does not increase the risk of IASD.  
 
Limitations 
First, it should be considered that this study has a retrospective design: all data, although deriving 
from a single high volume center involving a limited number of experienced operators following 
a standardized technique, have been retrospectively collected and analyzed. Second, despite all 
TEE examinations were performed by three experienced physicians, inter-operator accordance 
and/or agreement may not be examined. In addition, anatomical details concerning each 
individual PFO and IASD, given the study design, have not been included due to lack of uniform 
data recording. Third, the limited number of new onset IASD detected, derived from the low 
incidence of the phenomenon, may have reduced the statistical power of the conclusion. Fourth, 
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IASD have been evaluated at the time of the redo AFCA procedure and no temporal trend to 
evaluate the timing of eventual spontaneous closures over time is available.  
 
 
Conclusion 
LA access via a PFO or a single TS puncture for both the mapping and ablation catheters in a 
large cohort of patients undergoing AFCA did not lead to a relevant risk of IASD both during the 
first than the redo procedure. IASD are not predicted by any clinical or echocardiographic 
parameter and represent a sporadic, asymptomatic phenomenon not leading to any 
clinical/procedural implication. 
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Table 1. Clinical and echocardiographic characteristics of the study population stratified by 
presence of baseline patent foramen ovale. AF, atrial fibrillation. AP, antero-posterior diameter. 
BMI, body mass index. CM, cardiomyopathy. EF ejection fraction. HD heart disease. HF heart 
failure. LA, left atrium. LM, latero-medial diameter.  RA, right atrium. SI, supero-inferior 
diameter.  TIA, transient ischemic attack.  
Parameter 
Total  
197 pts 
PFO abstent  
154 pts (78.2%) 
PFO present 
 43 pts (21.8%) 
p value 
Age (%) 57.1 ± 10 57.7 ± 10 55.0 ± 9 0.12 
Male sex 150 (76.1) 118 (76.6) 32 (74.4) 0.76 
BMI 26.8 ± 4 26.7 ± 4 27.0 ± 3 0.64 
Arterial hypertension 86 (43.7) 68 (44.2) 18 (41.9) 0.79 
Hyperthyroidism 26 (13.2) 22 (14.3) 4 (9.3) 0.46 
Hypothyroidism 17 (8.6) 16 (10.4) 1 (2.3) 0.13 
Dyslipidemia 48 (24.4) 36 (23.4) 12 (27.9) 0.54 
Stroke/TIA 17 (8.6) 12 (7.8) 5 (11.6) 0.54 
Diabetes 9 (4.6) 7 (4.5) 2 (4.7) 1.00 
Congestive HF 12 (6.1) 9 (5.8) 3 (7.0) 0.73 
CHA2DS2VASc    
                          0 
                          1 
                          2 
                         > 2 
 
63 (32.0) 
67 (34.0) 
33 (16.8) 
34 (17.2) 
 
50 (32.5) 
51 (33.1) 
26 (16.9) 
27 (17.5) 
 
13 (30.2) 
16 (37.2) 
7 (16.3) 
7 (16.3) 
 
0.71 
Structural HD 
      Absent 
      Ischaemic HD 
      Valvular HD 
      Hypertrophic CM 
      Dilated CM 
 
151 (76.6) 
4 (2.0) 
18 (9.2) 
17 (8.6) 
7 (3.6) 
 
117 (76.1) 
3 (1.9) 
15 (9.7) 
15 (9.7) 
4 (2.6) 
 
34 (79.0) 
1 (2.3) 
3 (7.0) 
2 (4.7) 
3 (7.0) 
 
0.53 
Type of AF 
      Paroxysmal 
      Persistent 
 
76 (38.6) 
121 (61.4) 
 
57 (37.0) 
97 (63.0) 
 
19 (44.2) 
24 (55.8) 
 
0.39 
Ecocardiographic features 
      EF (%) 
      LA diameter (mm) 
                  AP 
                  SI 
                  LM 
      RA diameter (mm) 
                  SI 
                  LM 
     Left appendage flux (cm/sec) 
     Left appendage area (cm
2
) 
 
58.2 ± 8 
 
46.3 ± 6 
62.9 ± 8 
48.5 ± 8 
 
50.6 ± 8 
40.0 ± 8 
67.7 ± 22 
5.0 ± 1 
 
58.5 ± 8 
 
46.4 ± 6 
63.2 ± 8 
48.5 ± 8 
 
50.5 ± 8 
39.8 ± 8 
67.2 ± 21 
5.0 ± 1 
 
57.1 ± 8 
 
45.7 ± 6 
61.8 ± 7 
48.2 ± 8 
 
51.0 ± 8 
40.6 ± 8 
69.6 ± 22 
5.0 ± 1 
 
0.31 
 
0.58 
0.42 
0.86 
 
0.76 
0.57 
0.56 
0.85 
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Table 2. Clinical. echocardiographic and ablation characteristics stratified by development of an 
iatrogenic atrial septal defect following the first or second atrial fibrillation ablation procedure. 
AF. atrial fibrillation. Abbreviations as in Table 1. 
Parameter 
No IASD  
185 pts (93.9%) 
New IASD  
12 pts (6.1%) 
p value 
Age (%) 56.8 ± 10 60.8 ± 7 0.16 
Male sex 141 (76.2) 9 (75.0) 0.92 
BMI 26.7 ± 4 27.4 ± 4 0.58 
Arterial hypertension 78 (42.2) 8 (66.7) 0.09 
Hyperthyroidism 25 (13.5) 1 (8.3) 1.00 
Hypothyroidism 16 (8.6) 1 (8.3) 1.00 
Dyslipidemia 47 (25.4) 1 (8.3) 0.30 
Stroke/TIA 16 (8.6) 1 (8.3) 1.00 
Diabetes 8 (4.3) 1 (8.3) 0.43 
Congestive HF 12 (6.5) 0 (0) 1.00 
CHA2DS2VASc    
                          0 
                          1 
                          2 
                         > 2 
 
60 (32.3) 
63 (34.1) 
31 (16.8) 
31 (16.8) 
 
3 (25.0) 
4 (33.3) 
2 (16.7) 
3 (25.0) 
 
0.72 
Structural HD 
      Absent 
      Ischaemic HD 
      Valvular HD 
      Hypertrophic CM 
      Dilated CM 
 
140 (75.7) 
4 (2.2) 
18 (9.7) 
16 (8.6) 
7 (3.8) 
 
11 (91.7) 
0 (0) 
0 (0) 
1 (8.3) 
0 (0) 
 
0.69 
Type of AF 
      Paroxysmal 
      Persistent 
 
71 (38.4) 
114 (61.6) 
 
5 (41.7) 
7 (58.3) 
 
0.82 
Ecocardiographic features 
      EF (%) 
      LA diameter (mm) 
                  AP 
                  SI 
                  LM 
      RA diameter (mm) 
                  SI 
                  LM 
     Left appendage flux (cm/sec) 
     Left appendage area (cm
2
) 
 
58.0 ± 8 
 
46.4 ± 6 
62.9 ± 8 
48.2 ± 8 
 
50.6 ± 8 
39.9 ± 8 
67.7 ± 22 
5.0 ± 1 
 
60.6 ± 5 
 
44.6 ± 6 
61.9 ± 7 
49.9 ± 7 
 
49.7 ± 7 
39.5 ± 6 
68.7 ± 18 
5.4 ± 1 
 
0.30 
 
0.38 
0.71 
0.55 
 
0.71 
0.84 
0.88 
0.42 
Ablation approach 
   PVI 
   PVI+LL 
   PVI+LL+CFAEs 
 
41 (22.2) 
121 (65.4) 
23 (12.4) 
 
0 (0.0) 
11 (91.7) 
1 (8.3) 
 
0.14 
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Figure legends 
 
Figure 1. Left atrium was accessed. in absence of a patent foramen ovale. by a guide wire 
introduced through a single transseptal puncture (panel A) with the use of an 8.5F long sheath 
and directed towards the left superior pulmonary vein (panel B). The 8F ablation catheter was 
then advanced into the left atrium. exchanged over the guide wire. through the same hole (panel 
C) and finally the long sheath was advanced again in the left atrium permitting the introduction of 
the mapping catheter (panel D).  
 
Figure 2. Study flowchart. AFCA. atrial fibriallation catheter ablation; IASD. iatrogenic atrial 
septal defect; PFO. patent foramen ovale 
 
Figure 3. Transesophageal echocardiography 60 degrees mid-esophageal views of the atrial 
septal before (panel A) and 10 months after (panel B) transcatether atrial fibrillation ablation 
showing the presence in the latter of a small iatrogenic atrial septal defect with a not 
hemodynamically not significant left-right shunt. 
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